<DOC>
	<DOC>NCT02737891</DOC>
	<brief_summary>Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a double-blind, randomized, placebo-controlled, multiple-dose, two-center, safety and efficacy study of co-administration of tesofensine/metoprolol treatment in subjects with T2DM. Study medication will be administered for ninety (90) days (+2 days after the final assessments with half-dose of metoprolol). Following all baseline assessments, eligible subjects will be randomly assigned to one of the two arms (1:1).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>1. Males and females 2. Confirmed diagnosis of T2DM 3. 1870 years of age 4. HbA1c â‰¥7.0% 1. Hypersensitivity to tesofensine/metoprolol 2. Heart failure class II or greater according to the New York Heart Association (NYHA) or decompensated heart failure 3. History of myocardial infarction or stroke within 12 months prior to enrolment 4. History of coronary revascularisation or angioplasty in the last 12 months prior to enrolment 5. Patients reporting angina in the last 6 months prior to enrolment 6. Treatment with insulin and/or other injectable antidiabetic medications, or TZDs 7. Any clinically significant cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>